AR033403A1 - Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida. - Google Patents
Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida.Info
- Publication number
- AR033403A1 AR033403A1 ARP010105305A ARP010105305A AR033403A1 AR 033403 A1 AR033403 A1 AR 033403A1 AR P010105305 A ARP010105305 A AR P010105305A AR P010105305 A ARP010105305 A AR P010105305A AR 033403 A1 AR033403 A1 AR 033403A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- tumor
- solid tumor
- manufacture
- reduce
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 241000702263 Reovirus sp. Species 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 10
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
El uso de una cantidad efectiva de virus que es para la fabricacion de un medicamento mediante la administracion de un virus a un sujeto que porta un tumor solido para reducir el crecimiento del tumor, en donde el virus es capaz de matar selectivamente a las células tumorales, mediante una administracion de base seleccionada entre el grupo que consiste en: (a) administrar una composicion que comprende el virus en multiples sitios dentro del tumor solido; y (b) administrar directamente en el tumor una composicion que comprende el virus en donde el volumen de la composicion es de entre aproximadamente un 10% y aproximadamente un 100% del volumen del tumor. Pueden adoptarse dos métodos para aumentar la cantidad de células tumorales dentro del tumor solido las cuales son expuestas al virus. El virus puede ser administrado en multiples sitios dentro del tumor solido, o el virus puede ser administrado a un sitio unico en un volumen tan grande que el virus administrado es capaz de alcanzar más células tumorales en el tumor solido. El virus utilizado preferentemente es un Reovirus humano de serotipo cepa Dearing.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25222100P | 2000-11-20 | 2000-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033403A1 true AR033403A1 (es) | 2003-12-17 |
Family
ID=22955106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105305A AR033403A1 (es) | 2000-11-20 | 2001-11-14 | Uso de reovirus para la fabricacion de un medicamento para reducir una masa tumoral solida. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20020061298A1 (es) |
| EP (1) | EP1335737A2 (es) |
| JP (1) | JP2004513184A (es) |
| AR (1) | AR033403A1 (es) |
| AU (1) | AU2002218087A1 (es) |
| BR (1) | BR0115127A (es) |
| CA (1) | CA2428805A1 (es) |
| IL (1) | IL154758A0 (es) |
| MX (1) | MXPA03004298A (es) |
| WO (1) | WO2002040042A2 (es) |
| ZA (1) | ZA200301850B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289423A1 (en) * | 1998-05-14 | 2011-03-02 | David N. Krag | System for bracketing tissue |
| EP1341465B1 (en) * | 1998-05-14 | 2010-01-27 | Calypso Medical, Inc | System for locating and defining a target location within a human body |
| EP1499355A4 (en) | 2001-12-07 | 2005-10-05 | Bayer Pharmaceuticals Corp | USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES |
| US8239002B2 (en) * | 2004-08-12 | 2012-08-07 | Novatek Medical Ltd. | Guiding a tool for medical treatment by detecting a source of radioactivity |
| WO2006016368A2 (en) | 2004-08-12 | 2006-02-16 | Navotek Medical Ltd. | Localization of a radioactive source within a body of a subject |
| US7952079B2 (en) * | 2004-08-12 | 2011-05-31 | Navotek Medical Ltd. | Localization of a radioactive source |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP1922113A1 (en) * | 2005-08-11 | 2008-05-21 | Navotek Medical Ltd. | Medical treatment system and method using radioactivity based position sensor |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| PL2948179T3 (pl) | 2013-01-25 | 2019-10-31 | Nanobiotix | Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| JP2018516256A (ja) | 2015-05-28 | 2018-06-21 | ナノビオティックスＮａｎｏｂｉｏｔｉｘ | 治療用ワクチンとしての使用のためのナノ粒子 |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| EP3829608B1 (en) | 2018-08-01 | 2024-01-10 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2689403A1 (fr) * | 1992-04-01 | 1993-10-08 | Celsa Lg | Dispositif d'injection d'un médicament via une chambre implantable et outil facilitant son utilisation. |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
-
2001
- 2001-11-08 AU AU2002218087A patent/AU2002218087A1/en not_active Abandoned
- 2001-11-08 CA CA002428805A patent/CA2428805A1/en not_active Abandoned
- 2001-11-08 JP JP2002542414A patent/JP2004513184A/ja active Pending
- 2001-11-08 BR BR0115127-4A patent/BR0115127A/pt not_active IP Right Cessation
- 2001-11-08 EP EP01996388A patent/EP1335737A2/en not_active Withdrawn
- 2001-11-08 IL IL15475801A patent/IL154758A0/xx unknown
- 2001-11-08 MX MXPA03004298A patent/MXPA03004298A/es unknown
- 2001-11-08 WO PCT/CA2001/001612 patent/WO2002040042A2/en not_active Ceased
- 2001-11-14 AR ARP010105305A patent/AR033403A1/es not_active Application Discontinuation
- 2001-11-15 US US09/987,687 patent/US20020061298A1/en not_active Abandoned
-
2003
- 2003-03-06 ZA ZA200301850A patent/ZA200301850B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002218087A1 (en) | 2002-05-27 |
| US20020061298A1 (en) | 2002-05-23 |
| MXPA03004298A (es) | 2004-02-12 |
| WO2002040042A3 (en) | 2002-09-06 |
| BR0115127A (pt) | 2004-02-17 |
| WO2002040042A2 (en) | 2002-05-23 |
| EP1335737A2 (en) | 2003-08-20 |
| CA2428805A1 (en) | 2002-05-23 |
| JP2004513184A (ja) | 2004-04-30 |
| ZA200301850B (en) | 2004-03-08 |
| IL154758A0 (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065970A2 (es) | Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion | |
| AR022090A1 (es) | PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN | |
| UY27553A1 (es) | Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
| AR023806A1 (es) | Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| AR037260A1 (es) | Formulaciones de proteinas de liberacion sostenida acuosas | |
| CO5160272A1 (es) | Combinacion de cerivastatina y fibratos | |
| KR900015754A (ko) | 전암 병소 전신요법용의 적어도 1종의 사이토킨을 함유하는 약제학적 조성물의 용도 | |
| AR017779A1 (es) | Formulaciones inyectables de larga actuacion y uso de la misma para la fabricacion de un preparado | |
| Neena et al. | An ancient herb aloevera in dentistry: A review | |
| AR044383A1 (es) | Composiciones farmaceuticas de vareniclina | |
| AR018166A1 (es) | Productos utilizables en el tratamiento de tumores, una composicion farmaceutica y el uso de una antraciclina sola o con un inhibidor de topoisomerasa iantineoplasico en la preparacion de medicamentos | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| MX173567B (es) | Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih | |
| CN108697750A (zh) | 新型虎杖提取物及它们作为光动力灭活剂的用途 | |
| AR053977A1 (es) | Composiciones farmaceuticas con enmascaramiento de sabor | |
| Krahenbuhl et al. | Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells | |
| AR042598A1 (es) | Composiciones de acetaminofeno | |
| DE60316714D1 (de) | Pharmazeutische formulierung enthaltend olanzapin | |
| KR101332563B1 (ko) | 포졸란을 포함하는 항염증성 약학 조성물 | |
| Vamshi et al. | Pharmacological and Non Pharmacological Management of OSMF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |